Premium
Single‐Center Experience with the Bicarbon Bileaflet Prosthetic Heart Valve in Japan
Author(s) -
Misawa Yoshio,
Saito Tsutomu,
Konishi Hiroaki,
Oki Shinichi,
Kaminishi Yuichiro,
Tezuka Yasuhiro,
Aizawa Kei,
Takahashi Hideki,
Hasegawa Nobuyuki,
Kamisawa Osamu,
Kato Morito,
Fuse Katsuo
Publication year - 2002
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2002.06987.x
Subject(s) - medicine , incidence (geometry) , mitral valve replacement , single center , surgery , cardiology , malignancy , myocardial infarction , aortic valve replacement , mechanical heart valve , stroke (engine) , mitral valve , heart valve , mechanical engineering , physics , engineering , stenosis , optics
We analyzed midterm results using the Bicarbon valve in a single center. Forty‐four patients had aortic valve replacement (AVR), 48 had mitral valve replacement (MVR), and 13 had both aortic and mitral valve replacement (DVR). The mean age of the 105 patients was 61.2 ± 11.3 years. The mean follow‐up was 1.8 ± 1.1 years with a cumulative follow‐up of 188 patient‐years. There were 5 early deaths (4.7%: 4 in the AVR group and 1 in the MVR group) and 5 late deaths (2.7% per patient‐year: 3 malignancy, 1 cerebral hemorrhage, 1 myocardial infarction). Survival at 3 years was 91 ± 4% in the AVR group, 92 ± 5% in the MVR group, and 66 ± 23% in the DVR group. The linearized incidence of thromboembolic complications, hemorrhagic complications, and paravalvular leaks in all patients was 1.06 ± 2.34%, 1.60 ± 2.53%, and 0.53 ± 2.22% per patient‐year, respectively. No other complications were observed. In conclusion, the Bicarbon prosthetic heart valve has shown excellent clinical results associated with a low incidence of valve‐related complications.